Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment

This study has been completed.
Sponsor:
Collaborators:
Kenya National AIDS & STI Control Programme
Ministry of Medical Services, Kenya
EngenderHealth
Cornell University
Information provided by:
FHI 360
ClinicalTrials.gov Identifier:
NCT01247844
First received: September 7, 2010
Last updated: February 18, 2011
Last verified: February 2011

September 7, 2010
February 18, 2011
September 2010
January 2011   (final data collection date for primary outcome measure)
  • Moderate and severe adverse events [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
    Removal of Shang Ring after curcumcision at 7 days
  • Moderate and severe adverse events [ Time Frame: 14 Days ] [ Designated as safety issue: Yes ]
    Shang Ring removal after circumcision at 14 days
  • Moderate and severe adverse events [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Shang Ring removal after ciscumcision at 21 days
Same as current
Complete list of historical versions of study NCT01247844 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment
Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment

The objective of this research study is to evaluate the safety and acceptability of the Shang Ring method of medical male circumcision. The Shang Ring is a new circumcision device with a potential role in the safe and cost-effective delivery of circumcision services. The device, developed in China, consists of two concentric plastic rings. Following a ring penile block, the smaller ring is fitted at the base of the coronal sulcus. The foreskin is everted over the inner ring and the larger outer ring is secured over the inner ring. The foreskin is excised and several nicks are made on the incision line to prevent formation of a constricting, circumferential scab. No suturing is required.

In this study, the investigators will evaluate wound healing of men randomized to removal of the Shang Ring at one of three different points in time (Days 7, 14 or 21). Leaving the device on for 14 or 21 days constitutes extended wear of the device.

Sites: Homa Bay District Hospital, Nyanza Province, Kenya

The objective of this research study is to evaluate the safety and acceptability of the Shang Ring method of medical male circumcision. The Shang Ring is a new circumcision device with a potential role in the safe and cost-effective delivery of circumcision services. The device, developed in China, consists of two concentric plastic rings. Following a ring penile block, the smaller ring is fitted at the base of the coronal sulcus. The foreskin is everted over the inner ring and the larger outer ring is secured over the inner ring. The foreskin is excised and several nicks are made on the incision line to prevent formation of a constricting, circumferential scab. No suturing is required.

In this study, we will evaluate wound healing of men randomized to removal of the Shang Ring at one of three different points in time (Days 7, 14 or 21). Leaving the device on for 14 or 21 days constitutes extended wear of the device.

Although male circumcision has a demonstrated protective effect against HIV transmission, currently available surgical techniques and devices have limitations for widespread deployment in resource-poor areas. High costs and scarcity of trained providers hinder access to male circumcision services in resource-poor areas. Its simple design sets the Shang Ring apart from other male circumcision techniques. The Shang Ring has the potential for safe, effective and inexpensive delivery of male circumcision by trained healthcare personnel in HIV endemic countries.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Male Circumcision
Device: Shang Ring
The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
  • No Intervention: 1
    removal of Shang Ring at 7 days
    Intervention: Device: Shang Ring
  • No Intervention: 2
    removal of Shang Ring at 14 days
    Intervention: Device: Shang Ring
  • No Intervention: 3
    removal of Shang Ring at 21 days
    Intervention: Device: Shang Ring
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must be aged 18 and 54 years;
  • Must be uncircumcised (on examination);
  • Must be in good general health;
  • Must be HIV sero-negative, with documentation of testing no mor than one week before the procedure;
  • Must be free of genital ulcerations or other visible signs of STI (on examination);
  • Must be able to understand study procedures and requirements of study participation;
  • Must agree to return to the healthcare facility for the full schedule of follow-up visits after his circumcision;
  • Must freely consent to participate in the study and sign a written informed consent form;
  • Must have a cell phone or access to a cell phone; and,
  • Must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.

Exclusion Criteria:

  • Has a known allergy or sensitivity to lidocaine or other local anesthesia;
  • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
  • Has an active genital infection, anatomic abnormality or other condition, which in the opinion of the surgeon, prevents the man from undergoing a circumcision;
  • Has known bleeding/clotting disorder (e.g. hemophilia); and,
  • Has thalassemia (an inherited autosomal recessive blood disease).
Male
18 Years to 54 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Kenya
 
NCT01247844
10214
No
David Sokal, M.D, FHI
FHI 360
  • Kenya National AIDS & STI Control Programme
  • Ministry of Medical Services, Kenya
  • EngenderHealth
  • Cornell University
Study Chair: Marc Goldstein, M.D. Weill Cornell Medical College, NY, USA
Study Chair: Mark Barone, DVM; MS EngenderHealth, NY, USA
Principal Investigator: Philip S. Li, MD Weill Medical College of Cornell University
Principal Investigator: Puneet Masson, MD Weill Medical College of Cornell University
Principal Investigator: Paul Perchal, MA EngenderHealth
Principal Investigator: Jared Moguche, MB ChB EngenderHealth
Principal Investigator: Quentin Awori, MB ChB Engender Health
Principal Investigator: Peter Cherutich, MB ChB MPH National AIDS/STD Control Programme, Nairobi, Kenya
Principal Investigator: Nicholas Muraguri, MB ChB MPH National AIDS/STD Control Programme
Principal Investigator: John Masasabi Wekesa, MB ChB MMed Ministry of Medical Services Nairobi Kenya
Principal Investigator: Robert Otieno Simba, MMed Homa Bay District Hospital
FHI 360
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP